Baird R W upgraded shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) to a strong-buy rating in a research note issued to investors on Tuesday morning, Zacks.com reports.
A number of other analysts have also issued reports on the company. Royal Bank of Canada lifted their price target on Contineum Therapeutics from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 14th. Robert W. Baird started coverage on shares of Contineum Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $32.00 target price on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $29.50.
Read Our Latest Stock Analysis on CTNM
Contineum Therapeutics Trading Up 0.1 %
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.02). As a group, equities analysts forecast that Contineum Therapeutics will post -2.04 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp acquired a new stake in shares of Contineum Therapeutics in the 2nd quarter valued at $356,000. Rhumbline Advisers acquired a new stake in Contineum Therapeutics during the 2nd quarter worth $118,000. Versant Venture Management LLC purchased a new position in shares of Contineum Therapeutics during the second quarter worth about $16,169,000. Johnson & Johnson purchased a new stake in shares of Contineum Therapeutics during the second quarter worth approximately $34,853,000. Finally, Sandia Investment Management LP purchased a new stake in shares of Contineum Therapeutics in the second quarter valued at about $88,000.
About Contineum Therapeutics
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
See Also
- Five stocks we like better than Contineum Therapeutics
- How Can Investors Benefit From After-Hours Trading
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Insider Trades May Not Tell You What You Think
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- There Are Different Types of Stock To Invest In
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.